Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c, provides guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $1.26, $0.11 better than the analyst estimate of $1.15. Revenue for the quarter came in at $298 million versus the consensus estimate of $294.15 million.

GUIDANCE:

Halozyme Therapeutics sees FY2025 EPS of $4.95-$5.35, versus the consensus of $5.05. Halozyme Therapeutics sees FY2025 revenue of $1.15-1.225 billion, versus the consensus of $1.184 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Evolution Petroleum to buy Midland Basin mineral rights for $16M
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance